Bioprogress General Discussion

Most speculation on a takeover was relying on a big increase in the SP, I think we can forget that at the moment. I would imagine RT is trying to safeguard the company by the complexity of its deals. We are no longer a standalone as we appear to have engaged in contracts that would make it very difficult, both in monetary and legal terms for a large Pharma to extricate the core technologies from the double track RT is taking.

I think this deal is a master stroke as it also provides leverage to BPRG in the take up of these technologies by other companies. Modernize or face ever increasing competition from the wannabies as they start penetrating your markets.